{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:13:13Z","timestamp":1794960793392,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-02998-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:46:07Z","timestamp":1780919167000},"page":"1647-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Mariana L.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokporn","family":"Nuantang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Hur\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"\u00c1vila-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Haumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesela","family":"Kostova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtane","family":"Le Toumelin-Braizat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guerlesquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Demarles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Merdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Cauquil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-7860","authenticated-orcid":false,"given":"Oumou","family":"Goundiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Courtade-Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Valour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Zerhouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Artus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Douillet-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ovreiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duvauchelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matyas","family":"Ecsedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Colland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Geneste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-3040","authenticated-orcid":false,"given":"Ana Leticia","family":"Maragno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Ghysdael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-2626","authenticated-orcid":false,"given":"Christine","family":"Tran Quang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2998_CR1","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.","journal-title":"Blood"},{"key":"2998_CR2","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/JCO.23.00088","volume":"41","author":"EA Raetz","year":"2023","unstructured":"Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023;41:5025\u201334.","journal-title":"J Clin Oncol"},{"key":"2998_CR3","doi-asserted-by":"publisher","first-page":"E245","DOI":"10.1002\/ajh.25896","volume":"95","author":"B Samra","year":"2020","unstructured":"Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, et al. Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020;95:E245\u2013E247.","journal-title":"Am J Hematol"},{"key":"2998_CR4","doi-asserted-by":"crossref","unstructured":"Hughes AD, P\u00f6l\u00f6nen P, Teachey DT. Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. Haematologica. 2025;110:1934\u201350.","DOI":"10.3324\/haematol.2024.285643"},{"key":"2998_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"PE Czabotar","year":"2023","unstructured":"Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat Rev Mol Cell Biol. 2023;24:732\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2998_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2998_CR7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"2998_CR8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128:1382\u201395.","journal-title":"Blood"},{"key":"2998_CR9","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/bloodadvances.2022007728","volume":"7","author":"EA Olesinski","year":"2023","unstructured":"Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, et al. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023;7:2917\u201323.","journal-title":"Blood Adv"},{"key":"2998_CR10","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","volume":"29","author":"C Saygin","year":"2023","unstructured":"Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, et al. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023;29:3151\u201361.","journal-title":"Clin Cancer Res"},{"key":"2998_CR11","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","volume":"20","author":"S Suryani","year":"2014","unstructured":"Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20:4520\u201331.","journal-title":"Clin Cancer Res"},{"key":"2998_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell"},{"key":"2998_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1084\/jem.20110750","volume":"208","author":"EC Josefsson","year":"2011","unstructured":"Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011;208:2017\u201331.","journal-title":"J Exp Med"},{"key":"2998_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663\u201374.","journal-title":"Blood"},{"key":"2998_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"2998_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348\u201360.","journal-title":"Blood Adv"},{"key":"2998_CR17","first-page":"2657","volume":"147","author":"J Lund","year":"1991","unstructured":"Lund J, Winter G, Jones PT, Pound JD, Tanaka T, Walker MR, et al. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J Immunol Baltim Md 1950. 1991;147:2657\u201362.","journal-title":"J Immunol Baltim Md 1950"},{"key":"2998_CR18","doi-asserted-by":"publisher","first-page":"20075","DOI":"10.18632\/oncotarget.24744","volume":"9","author":"P Casara","year":"2018","unstructured":"Casara P, Davidson J, Claperon A, Toumelin-Braizat GL, Vogler M, Bruno A, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9:20075\u201388.","journal-title":"Oncotarget"},{"key":"2998_CR19","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.","journal-title":"Sci Transl Med"},{"key":"2998_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29:909\u201316.","journal-title":"J Clin Oncol"},{"key":"2998_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7120","volume":"10","author":"AS Judd","year":"2024","unstructured":"Judd AS, Bawa B, Buck WR, Tao Z-F, Li Y, Mitten MJ, et al. BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Sci Adv. 2024;10:eado7120.","journal-title":"Sci Adv"},{"key":"2998_CR22","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 A-M, Renders S, Stumpf K, Reyneri C, Betz B, et al. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax. Cancer Discov. 2023;13:1408\u201327.","journal-title":"Cancer Discov"},{"key":"2998_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2019.100640","volume":"74","author":"J Calvo","year":"2019","unstructured":"Calvo J, Fahy L, Uzan B, Pflumio F. Desperately seeking a home marrow niche for T-cell acute lymphoblastic leukaemia. Adv Biol Regul. 2019;74:100640.","journal-title":"Adv Biol Regul"},{"key":"2998_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"2998_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/bloodadvances.2024013423","volume":"9","author":"S Kannan","year":"2025","unstructured":"Kannan S, Li Y, Baran N, Yang X, Ghotbaldini S, Zhang Tatarata Q, et al. Antileukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025;9:473\u201387.","journal-title":"Blood Adv"},{"key":"2998_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/biom14010106","volume":"14","author":"S Wang","year":"2024","unstructured":"Wang S, Zhang R, Zhong K, Guo W, Tong A. An Anti-CD7 Antibody\u2013Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL). Biomolecules. 2024;14:106.","journal-title":"Biomolecules"},{"key":"2998_CR27","doi-asserted-by":"publisher","first-page":"34070","DOI":"10.18632\/oncotarget.8710","volume":"7","author":"J Tang","year":"2016","unstructured":"Tang J, Li J, Zhu X, Yu Y, Chen D, Yuan L, et al. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget. 2016;7:34070\u201383.","journal-title":"Oncotarget"},{"key":"2998_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","volume":"9","author":"MR Luskin","year":"2025","unstructured":"Luskin MR, Shimony S, Keating J, Winer ES, Garcia JS, Stone RM, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025;9:617\u201326.","journal-title":"Blood Adv"},{"key":"2998_CR29","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/s41375-024-02414-4","volume":"38","author":"F Ravandi","year":"2024","unstructured":"Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024;38:2717\u201321.","journal-title":"Leukemia"},{"key":"2998_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/bloodadvances.2025016565","volume":"10","author":"NJ Short","year":"2026","unstructured":"Short NJ, Kantarjian H, Jain N, Kadia TM, Senapati J, Haddad FG, et al. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia. Blood Adv. 2026;10:25\u201328.","journal-title":"Blood Adv"},{"key":"2998_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, et al. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers. 2021;14:150.","journal-title":"Cancers"},{"key":"2998_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1046\/j.1365-2141.1996.d01-1720.x","volume":"93","author":"L Ginaldi","year":"1996","unstructured":"Ginaldi L, Matutes E, Farahat N, De Martinis M, Morilla R, Catovsky D. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol. 1996;93:921\u20137.","journal-title":"Br J Haematol"},{"key":"2998_CR33","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","volume":"130","author":"B Boidol","year":"2017","unstructured":"Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, G\u00fcltekin S, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130:2499\u2013503.","journal-title":"Blood"},{"key":"2998_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2141.2011.08870.x","volume":"155","author":"S Hussein","year":"2011","unstructured":"Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, et al. Aberrant T-cell antigen expression in B lymphoblastic leukaemia. Br J Haematol. 2011;155:449\u201356.","journal-title":"Br J Haematol"},{"key":"2998_CR35","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood.V81.9.2399.2399","volume":"81","author":"K Kita","year":"1993","unstructured":"Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia\/Lymphoma. Blood. 1993;81:2399\u2013405.","journal-title":"Blood"},{"key":"2998_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/(SICI)1096-8652(199808)58:4<278::AID-AJH5>3.0.CO;2-N","volume":"58","author":"A Saxena","year":"1998","unstructured":"Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol. 1998;58:278\u201384.","journal-title":"Am J Hematol"},{"key":"2998_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.leukres.2006.06.001","volume":"31","author":"H Chang","year":"2007","unstructured":"Chang H, Yeung J, Brandwein J, Yi Q-L. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res. 2007;31:157\u201362.","journal-title":"Leuk Res"},{"key":"2998_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12185-021-03182-y","volume":"114","author":"K Lv","year":"2021","unstructured":"Lv K, Cai C, Chen J, Xu M, Wan L, Zhou M, et al. Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission. Int J Hematol. 2021;114:464\u201371.","journal-title":"Int J Hematol"},{"key":"2998_CR39","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","volume":"26","author":"SB Balachander","year":"2020","unstructured":"Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, et al. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. Clin Cancer Res. 2020;26:6535\u201349.","journal-title":"Clin Cancer Res"},{"key":"2998_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3324\/haematol.2023.284353","volume":"110","author":"J Ravikrishnan","year":"2025","unstructured":"Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai T-H, Misra S, et al. LP-118 is a novel B-cell lymphoma 2 \/ extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025;110:78\u201391.","journal-title":"Haematologica"},{"key":"2998_CR41","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"2998_CR42","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","volume":"108","author":"Y Jia","year":"2023","unstructured":"Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023;108:2626\u201338.","journal-title":"Haematologica"},{"key":"2998_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112186","volume":"192","author":"X Zhang","year":"2020","unstructured":"Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186.","journal-title":"Eur J Med Chem"},{"key":"2998_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-022-04490-8","volume":"91","author":"A Jaiswal","year":"2023","unstructured":"Jaiswal A, Jaiswal A, Williamson EA, Gelfond J, Zheng G, Zhou D, et al. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis. Cancer Chemother Pharmacol. 2023;91:89\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2998_CR45","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang L, Riley-Gillis B, Vijay P, Shen Y. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes. Mol Cancer Ther. 2019;18:1302\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2998_CR46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers. 2023;15:1278.","journal-title":"Cancers"},{"key":"2998_CR47","doi-asserted-by":"crossref","unstructured":"Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ et al. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma 2025;66:1\u201312.","DOI":"10.1080\/10428194.2025.2449582"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02998-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02998-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02998-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:44Z","timestamp":1785521084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02998-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02998-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ALM, LB, GLTB, TN, VK, DD, A-AA, SH, JGuerlesquin, NC, SCG, DV, OGoundiam, ME, MM, MZ, RA, EDM, IL, AD, AO, BD are employees of Servier. FC and OG have been employees of Servier and are currently employees of Pierre Fabre Laboratories. FR has been employee of Servier and is currently employee of Boehringer Ingelheim. MLO was supported by a postdoctoral fellowship from Servier. KN and GH were supported by funds from Servier.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All PDXs were derived from patients\u2019 T-ALL diagnostic samples included in the GRAALL-2005 study or in the FRALLE protocol and informed consent was obtained from all patients at trial entry (trial registration ID: NCT00327678). Studies were conducted in accordance with the Declaration of Helsinki and approved by local and multicenter research ethical committees.","order":2,"name":"Ethics","label":"Consent to participate statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}